1e
19
1
49
2
2
18
1b
1d
18
38
69
1d
2 29
1d
25
Barbara K Schmidt, MD, MSc
88
69
Emeritus Professor CE of Pediatrics (Neonatology & Newborn Services)
7
61
Department: Pediatrics
4
1
b
1d
46
Contact information
58
4
3
3
3
2
4
b
1f
58
Hospital of the University of Pennsylvania
34 Division of Neonatology and Newborn Services
3f 3400 Spruce Street, 8 Ravdin
Philadelphia, PA 19104
26
34 Division of Neonatology and Newborn Services
3f 3400 Spruce Street, 8 Ravdin
Philadelphia, PA 19104
30
Office: (215) 662-3228
34 Fax: (215) 349-8831
24
9d
12
34 Fax: (215) 349-8831
24
13
Education:
21 7 MD c
30 Georg-August University, 1976.
21 e MD Thesis c
30 Georg-August University, 1977.
21 8 MSc 34 (Clinical Epidemiology and Biostatistics) c
2c McMaster University, 1992.
c
3
3
3
3
8d
Permanent link21 7 MD c
30 Georg-August University, 1976.
21 e MD Thesis c
30 Georg-August University, 1977.
21 8 MSc 34 (Clinical Epidemiology and Biostatistics) c
2c McMaster University, 1992.
c
2 29
21
1e
1d
24
5e
8
4af Dr. Schmidt’s research focuses on collaborative neonatal randomized trials that have clinically important, long-term outcomes such as growth and development. Examples of trials she directed in the past include the “Trial of Indomethacin Prophylaxis in Preterms.” In this study, 1,202 extremely low-birth-weight infants from five countries were followed to the end of the second year of life. The results from the study showed that the high rate of mental and motor deficits in these children is not improved by prophylactic treatment with indomethacin. She is also the principal investigator of the “Caffeine for Apnea of Prematurity” trial, which enrolled over 2,000 very low-birth-weight infants in North America, Europe, Israel and Australia. Caffeine has been used for more than 30 years to regulate the breathing of very preterm babies, but without sufficient knowledge of the possible benefits and risks. To date, this trial has shown that caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability up to two years after very preterm birth. This study will continue to follow the study participants well into school age.
8
2cb Since May 2010, Dr. Schmidt is a Co-Principal Investigator of the Data Coordinating Center for the Prematurity and Respiratory Outcomes Program (PROP) sponsored by NHLBI and located at the University of Pennsylvania School of Medicine. One of the goals of this multi-center collaboration is the identification of predictors of respiratory outcomes that may serve as surrogate endpoints in future trials of prevention and therapy of respiratory diseases in preterm infants. In addition, since April 2011, Dr. Schmidt is the clinical center PI for the University of Pennsylvania and Children’s Hospital of Philadelphia in the reconfigured Neonatal Research Network (NRN) of the Eunice Kennedy Shriver NICHD.
26 29
27
Description of Research Expertise
16e Barbara Schmidt, MD, MSc, is a Professor of Pediatrics and Senior Scholar in the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania School of Medicine. She is also a staff neonatologist in the Division of Neonatology at the Children’s Hospital of Philadelphia and the University of Pennsylvania Health System.8
4af Dr. Schmidt’s research focuses on collaborative neonatal randomized trials that have clinically important, long-term outcomes such as growth and development. Examples of trials she directed in the past include the “Trial of Indomethacin Prophylaxis in Preterms.” In this study, 1,202 extremely low-birth-weight infants from five countries were followed to the end of the second year of life. The results from the study showed that the high rate of mental and motor deficits in these children is not improved by prophylactic treatment with indomethacin. She is also the principal investigator of the “Caffeine for Apnea of Prematurity” trial, which enrolled over 2,000 very low-birth-weight infants in North America, Europe, Israel and Australia. Caffeine has been used for more than 30 years to regulate the breathing of very preterm babies, but without sufficient knowledge of the possible benefits and risks. To date, this trial has shown that caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability up to two years after very preterm birth. This study will continue to follow the study participants well into school age.
8
2cb Since May 2010, Dr. Schmidt is a Co-Principal Investigator of the Data Coordinating Center for the Prematurity and Respiratory Outcomes Program (PROP) sponsored by NHLBI and located at the University of Pennsylvania School of Medicine. One of the goals of this multi-center collaboration is the identification of predictors of respiratory outcomes that may serve as surrogate endpoints in future trials of prevention and therapy of respiratory diseases in preterm infants. In addition, since April 2011, Dr. Schmidt is the clinical center PI for the University of Pennsylvania and Children’s Hospital of Philadelphia in the reconfigured Neonatal Research Network (NRN) of the Eunice Kennedy Shriver NICHD.
26 29
23
f9 Whyte RK, Nelson H, Roberts RS, Schmidt B: Benefits of Oxygen Saturation Targeting Trials: Oximeter Calibration Software Revision and Infant Saturations. J Pediatr March 2017.
1c6 Jensen EA, Dysart KC, Gantz MG, Carper B, Higgins RD, Keszler M, Laughon MM, Poindexter BB, Stoll BJ, Walsh MC, Schmidt B; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network: Association Between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. J Pediatr February 2017.
102 Jensen EA, Panitch H, Feng R, Moore PE, Schmidt B: Interobserver Reliability of the Respiratory Physical Examination in Premature Infants: A Multicenter Study. J Pediatr November 2016.
14d Schmidt B, Whyte RK, Shah PS, Abbasi S, Bairam A, Harrold J, Roberts RS; Canadian Oxygen Trial (COT) Group: Effects of Targeting Higher or Lower Oxygen Saturations in Centers with More Versus Less Separation between Median Saturations. J Pediatr November 2016.
136 Das A, Tyson J, Pedroza C, Schmidt B, Gantz M, Wallace D, Truog WE, Higgins RD: Methodological Issues in the Design and Analyses of Neonatal Research Studies: Experience of the NICHD Neonatal Research Network. Semin Perinatol June 2016.
165 Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, Reynolds AM, Shaw PA, Jobe AH: Comparisons and Limitations of Current Definitions Bronchopulmonary Dysplasia. Ann Am Thorac Soc December 2015 Notes: Prematurity and Respiratory Outcomes Program.
1ad Schmidt B, Roberts RS, Davis PG, Doyle LW, Asztalos EV, Opie G, Bairam A, Solimano A, Arnon S, Sauve RS: Prediction of Late Death or Disability at Age 5 Years Using a Count of 3 Neonatal Morbidities in Very Low Birth Weight Infants. J Pediatr November 2015 Notes: Caffeine for Apnea of Prematurity (CAP) Trial Investigators
17f Poets CF, Roberts RS, Schmidt B, Whyte RK, Asztalos EV, Bader D, Bairam A, Moddemann D, Peliowski A, Rabi Y, Solimano A, Nelson H: Association Between Intermittent Hypoxemia or Bradycardia and Late Death or Disability in Extremely Preterm Infants. JAMA August 2015 Notes: Canadian Oxygen Trial Investigators.
167 Synnes A, Anderson PJ, Grunau RE, Dewey D, Moddemann D, Tin W, Davis PG, Doyle LW, Foster G, Khairy M, Nwaesei C, Schmidt B: Predicting severe motor impairment in preterm children at age 5 years. Arch Dis Child August 2015 Notes: CAP Trial Investigator group.
2c
7
1d
1f
Selected Publications
1f8 Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, Dewey D, D'llario J, Doyle LW, Grunau RE, Moddemann D, Nelson H, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity (CAP) Trial Group: Academic Performance, Motor Function, and Behavior 11 Years After neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year follow-up of the CAP Randomized Clinical Trial. JAMA Pediatr April 2017.f9 Whyte RK, Nelson H, Roberts RS, Schmidt B: Benefits of Oxygen Saturation Targeting Trials: Oximeter Calibration Software Revision and Infant Saturations. J Pediatr March 2017.
1c6 Jensen EA, Dysart KC, Gantz MG, Carper B, Higgins RD, Keszler M, Laughon MM, Poindexter BB, Stoll BJ, Walsh MC, Schmidt B; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network: Association Between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. J Pediatr February 2017.
102 Jensen EA, Panitch H, Feng R, Moore PE, Schmidt B: Interobserver Reliability of the Respiratory Physical Examination in Premature Infants: A Multicenter Study. J Pediatr November 2016.
14d Schmidt B, Whyte RK, Shah PS, Abbasi S, Bairam A, Harrold J, Roberts RS; Canadian Oxygen Trial (COT) Group: Effects of Targeting Higher or Lower Oxygen Saturations in Centers with More Versus Less Separation between Median Saturations. J Pediatr November 2016.
136 Das A, Tyson J, Pedroza C, Schmidt B, Gantz M, Wallace D, Truog WE, Higgins RD: Methodological Issues in the Design and Analyses of Neonatal Research Studies: Experience of the NICHD Neonatal Research Network. Semin Perinatol June 2016.
165 Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, Reynolds AM, Shaw PA, Jobe AH: Comparisons and Limitations of Current Definitions Bronchopulmonary Dysplasia. Ann Am Thorac Soc December 2015 Notes: Prematurity and Respiratory Outcomes Program.
1ad Schmidt B, Roberts RS, Davis PG, Doyle LW, Asztalos EV, Opie G, Bairam A, Solimano A, Arnon S, Sauve RS: Prediction of Late Death or Disability at Age 5 Years Using a Count of 3 Neonatal Morbidities in Very Low Birth Weight Infants. J Pediatr November 2015 Notes: Caffeine for Apnea of Prematurity (CAP) Trial Investigators
17f Poets CF, Roberts RS, Schmidt B, Whyte RK, Asztalos EV, Bader D, Bairam A, Moddemann D, Peliowski A, Rabi Y, Solimano A, Nelson H: Association Between Intermittent Hypoxemia or Bradycardia and Late Death or Disability in Extremely Preterm Infants. JAMA August 2015 Notes: Canadian Oxygen Trial Investigators.
167 Synnes A, Anderson PJ, Grunau RE, Dewey D, Moddemann D, Tin W, Davis PG, Doyle LW, Foster G, Khairy M, Nwaesei C, Schmidt B: Predicting severe motor impairment in preterm children at age 5 years. Arch Dis Child August 2015 Notes: CAP Trial Investigator group.
2c